IFP Advisors Inc boosted its holdings in Teladoc (NYSE:TDOC) by 17,522.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 73,663 shares of the health services provider’s stock after buying an additional 73,245 shares during the quarter. IFP Advisors Inc owned approximately 0.12% of Teladoc worth $2,969,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of TDOC. California Public Employees Retirement System increased its holdings in Teladoc by 52.1% in the third quarter. California Public Employees Retirement System now owns 11,409 shares of the health services provider’s stock valued at $378,000 after buying an additional 3,909 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Teladoc by 12.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 249,789 shares of the health services provider’s stock valued at $8,706,000 after buying an additional 28,038 shares during the last quarter. Strs Ohio increased its holdings in Teladoc by 33.3% in the fourth quarter. Strs Ohio now owns 304,226 shares of the health services provider’s stock valued at $10,602,000 after buying an additional 76,057 shares during the last quarter. SG Americas Securities LLC purchased a new position in Teladoc in the fourth quarter valued at $101,000. Finally, Riverbridge Partners LLC grew its holdings in shares of Teladoc by 44.1% during the fourth quarter. Riverbridge Partners LLC now owns 859,018 shares of the health services provider’s stock worth $29,937,000 after purchasing an additional 262,959 shares during the last quarter.
NYSE TDOC opened at $50.60 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15. Teladoc has a 52-week low of $27.30 and a 52-week high of $50.70. The stock has a market cap of $3.11 billion, a P/E ratio of -30.67 and a beta of 0.35.
Teladoc (NYSE:TDOC) last released its quarterly earnings results on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.04. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The firm had revenue of $89.64 million for the quarter, compared to analyst estimates of $86.77 million. During the same quarter last year, the company posted ($0.30) earnings per share. The business’s revenue was up 109.0% on a year-over-year basis. analysts predict that Teladoc will post -1.37 earnings per share for the current fiscal year.
In related news, President Peter A. Mcclennen sold 27,533 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $43.01, for a total transaction of $1,184,194.33. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jason N. Gorevic sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $48.93, for a total value of $1,223,250.00. Following the transaction, the chief executive officer now directly owns 636,184 shares in the company, valued at approximately $31,128,483.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 483,954 shares of company stock worth $19,960,682. Corporate insiders own 3.95% of the company’s stock.
Several brokerages have issued reports on TDOC. KeyCorp reaffirmed an “overweight” rating and set a $50.00 price objective (up previously from $41.00) on shares of Teladoc in a report on Thursday, March 15th. Jefferies Group began coverage on Teladoc in a report on Friday, January 26th. They set a “buy” rating and a $40.00 price objective on the stock. Deutsche Bank lowered Teladoc from a “buy” rating to a “hold” rating and set a $45.00 price objective on the stock. in a report on Thursday, March 15th. Craig Hallum set a $39.00 price objective on Teladoc and gave the stock a “hold” rating in a report on Wednesday, May 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $45.00 price objective on shares of Teladoc in a report on Friday, April 13th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $42.67.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc (NYSE:TDOC).
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.